Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Galmed Pharmaceuticals (GLMD)
NASDAQ:GLMD
reports
Galmed Pharmaceuticals (GLMD) Stock Price & Analysis
1,144 Followers
GLMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.43 - $14.18
Previous Close$4.34
Volume7.50K
Average Volume (3M)24.43K
Market Cap
$7.28M
Enterprise Value-$6.04M
Total Cash (Recent Filing)$13.90M
Total Debt (Recent Filing)$578.00K
Price to Earnings (P/E)-0.5
Beta0.89
Next Earnings
Aug 03, 2023EPS Estimate
-$1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.08
Shares Outstanding21,113,066
10 Day Avg. Volume7,066
30 Day Avg. Volume24,433
Standard Deviation0.25
R-Squared0.06
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.54
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-41.79
Enterprise Value/Ebitda0.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Galmed Pharmaceuticals News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GLMD FAQ
What was Galmed Pharmaceuticals’s price range in the past 12 months?
Galmed Pharmaceuticals lowest stock price was $3.43 and its highest was $14.18 in the past 12 months.
What is Galmed Pharmaceuticals’s market cap?
Currently, no data Available
When is Galmed Pharmaceuticals’s upcoming earnings report date?
Galmed Pharmaceuticals’s upcoming earnings report date is Aug 03, 2023 which is in 55 days.
How were Galmed Pharmaceuticals’s earnings last quarter?
Galmed Pharmaceuticals released its earnings results on Jun 01, 2023. The company reported -$1.09 earnings per share for the quarter, beating the consensus estimate of -$1.5 by $0.41.
Is Galmed Pharmaceuticals overvalued?
According to Wall Street analysts Galmed Pharmaceuticals’s price is currently Overvalued.
Does Galmed Pharmaceuticals pay dividends?
Galmed Pharmaceuticals does not currently pay dividends.
What is Galmed Pharmaceuticals’s EPS estimate?
Galmed Pharmaceuticals’s EPS estimate is -$1.5.
How many shares outstanding does Galmed Pharmaceuticals have?
Galmed Pharmaceuticals has 1,680,226 shares outstanding.
What happened to Galmed Pharmaceuticals’s price movement after its last earnings report?
Galmed Pharmaceuticals reported an EPS of -$1.09 in its last earnings report, beating expectations of -$1.5. Following the earnings report the stock price went up 0.434%.
Which hedge fund is a major shareholder of Galmed Pharmaceuticals?
Among the largest hedge funds holding Galmed Pharmaceuticals’s share is PYA Waltman Capital, LLC. It holds Galmed Pharmaceuticals’s shares valued at N/A.
---
Galmed Pharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 67.0 Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.96%
12-Months-Change
Fundamentals
Return on Equity
-74.56%
Trailing 12-Months
Asset Growth
-51.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
---
---